Home » Stocks » WVE

Wave Life Sciences Ltd. (WVE)

Stock Price: $6.27 USD -0.07 (-1.10%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $6.66 +0.39 (6.22%) Apr 16, 7:08 PM
Market Cap 307.21M
Revenue (ttm) 20.08M
Net Income (ttm) -149.91M
Shares Out 49.00M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $6.27
Previous Close $6.34
Change ($) -0.07
Change (%) -1.10%
Day's Open 6.40
Day's Range 6.10 - 6.53
Day's Volume 334,179
52-Week Range 4.82 - 19.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AFMD, CMRX, EPZM, SEEL
2 weeks ago - 24/7 Wall Street

No one ever said drug development was easy.

2 weeks ago - The Motley Fool

Wave Life Sciences Ltd's (NASDAQ: WVE) closely-watched antisense oligonucleotide program crashed in an early-stage Huntington's disease study, thus wiping out two experimental drug candidates. What Happ...

2 weeks ago - Benzinga

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101

2 weeks ago - GlobeNewsWire

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

3 weeks ago - Zacks Investment Research

CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battlin...

4 weeks ago - GlobeNewsWire

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -7.27% and -30.61%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 64.24% year over year to ($0.59), which beat the estimat...

1 month ago - Benzinga

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

1 month ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

2 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -17.81% and -76.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021

5 months ago - GlobeNewsWire

Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

6 months ago - GlobeNewsWire

Investors liked an analyst's upgrade of the biotech stock.

6 months ago - The Motley Fool

CAMBRIDGE, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

6 months ago - GlobeNewsWire

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Other stocks mentioned: BBC, BTEC, IBBJ, IDNA, MRNS, NVUS, PTH ...
6 months ago - Zacks Investment Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battl...

7 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.65% and -57.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) moved higher by 1% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021

8 months ago - GlobeNewsWire

Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD

8 months ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battli...

8 months ago - GlobeNewsWire

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Newly created position will focus on translating advancements from PRISM platform into new therapeutic candidates Newly created position will focus on translating advancements from PRISM platform into n...

10 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -2.99% and -42.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.

11 months ago - Benzinga

Data from both PRECISION-HD clinical trials expected in 2H 2020

11 months ago - GlobeNewsWire

Wave Life Sciences Ltd. (WVE) CEO Dr.

1 year ago - Seeking Alpha

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.49% and -57.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Wave Life Sciences (WVE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Wave Life Sciences Ltd. (WVE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial. The post Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease...

1 year ago - InvestorPlace

Wave Life Sciences Ltd. (NASDAQ: WVE) shares dropped sharply to start out the week after the company announced topline data from its ongoing midstage trial in Huntington’s disease.

1 year ago - 24/7 Wall Street

Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals. The post Why This Bio...

1 year ago - Investors Business Daily

Wipeout In Wave Life Sciences

1 year ago - Seeking Alpha

WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo

1 year ago - GlobeNewsWire

Investors need to pay close attention to Wave Life Sciences (WVE) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Wave Life Sciences (WVE) news for Monday about it giving up on a Duchenne muscular dystrophy drug is hitting WVE stock hard. The post Wave Life Sciences News: WVE Stock Slammed 54% by Duchenne Drug Fail...

1 year ago - InvestorPlace

About WVE

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials f... [Read more...]

Industry
Biotechnology
IPO Date
Nov 11, 2015
CEO
Paul Bolno
Employees
217
Stock Exchange
NASDAQ
Ticker Symbol
WVE
Full Company Profile

Financial Performance

In 2020, WVE's revenue was $20.08 million, an increase of 25.61% compared to the previous year's $15.98 million. Losses were -$149.91 million, -22.58% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for WVE stock is "Buy." The 12-month stock price forecast is 9.14, which is an increase of 45.77% from the latest price.

Price Target
$9.14
(45.77% upside)
Analyst Consensus: Buy